Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Exelixis

EXELNasdaqBiotechnologyWilmington, US-DE, USLarge capWebsite ↗
  • Russell 1000
  • MidCap 400

What Exelixis is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to July 3, 2026: $2.44 billion, up 9.4% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to July 3, 2026: $1.17 billion, up 56% from a year earlier.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to July 3, 2026: $0.01 billion, down 50% from a year earlier.SEC EDGAR filings (XBRL)
  • Share buybacks in the fiscal year to January 2, 2026: $0.95 billion.SEC EDGAR filings (10-K)
  • Latest earnings call or results release (August 5, 2026): sentiment 0.30 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
  • Guidance in the last 90 days: 0 outlook figures raised, 3 lowered, 3 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 10, 2026): 1 risk factor added, 1 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q3 2026: $0.5 million on the open market.SEC Form 4
  • 757 institutional managers reported a position at June 30, 2026 (+56 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 9 (11 a year earlier).U.S. Department of Labor (OFLC)

Company Posture

How Company Posture is measured →

Company Posture covers S&P 500 companies.

Credit

How these are built →

No bond term sheets or tagged debt on file for Exelixis yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Exelixis: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

$1.2BData to Jul 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Exelixis: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jul 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Exelixis: revenue, trailing twelve months

$ billions, from SEC filings

$2.4BData to Jul 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Exelixis: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$0.95BData to Jan 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Exelixis: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jul 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Exelixis: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

374,639Data to Sep 2018
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Exelixis: guidance raised minus lowered

Guidance Ledger statements by quarter

−3.0Data 22 days ago
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Exelixis: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.30Data to Aug 2026
ImageDataPalanor calculation
Business

Exelixis: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.70Data to Aug 2026
ImageDataPalanor calculation
Business

Exelixis: risk factors added per annual report

New Item 1A risk factors in each 10-K

1.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Exelixis: H-1B filings certified

Labor Condition Applications by quarter received

9.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Exelixis: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$0.5MData 22 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Exelixis: institutional holders

Managers reporting a position on Form 13F, by quarter

757.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 20, 2026Lobbying
    Lobbying report (TODD STRATEGY GROUP)third_quarter 2026 · $0.1 million
  2. Oct 20, 2026Lobbying
    Lobbying report (EXELIXIS INC.)third_quarter 2026 · $0.6 million
  3. Oct 19, 2026Lobbying
    Lobbying report (THORN RUN PARTNERS)third_quarter 2026 · $0.1 million
  4. Oct 19, 2026Lobbying
    Lobbying report (ARNOLD & PORTER KAYE SCHOLER LLP)third_quarter 2026 · $0.1 million
  5. Jul 21, 2026Lobbying
    Lobbying report (TODD STRATEGY GROUP)second_quarter 2026 · $0.1 million
  6. Jul 20, 2026Lobbying
    Lobbying report (EXELIXIS INC.)second_quarter 2026 · $0.6 million
  7. Jul 20, 2026Lobbying
    Lobbying report (ARNOLD & PORTER KAYE SCHOLER LLP)second_quarter 2026 · $0.1 million
  8. Jul 20, 2026Lobbying
    Lobbying report (W STRATEGIES, LLC)second_quarter 2026 · $0.1 million
  9. Jul 14, 2026Patent
    Patent granted: PD-L1 BINDING AGENTS AND USES THEREOFUS 12679893
  10. Jul 14, 2026Patent
    Patent granted: CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITORUS 12679809
  11. Jul 7, 2026Patent
    Patent granted: COMBINATIONS FOR THE TREATMENT OF CANCERUS 12673052
  12. May 29, 20268-K
    Director or officer changeItem 5.02
  13. May 29, 20268-K
    Shareholder vote resultsItem 5.07
  14. May 18, 2026Trademark
    Trademark application
  15. Feb 10, 202610-K
    Annual report (10-K)1 risk factors added, 1 removed
  16. Dec 23, 2025Patent
    Patent granted: Compounds for the Treatment of Kinase-Dependent DisordersUS 12503438
  17. Dec 16, 2025Patent
    Patent granted: Processes for the Preparation of a Kinase InhibitorUS 12497367
  18. Nov 7, 20258-K
    Director or officer changeItem 5.02
  19. Aug 29, 20258-K
    Director or officer changeItem 5.02
  20. Jun 2, 20258-K
    Shareholder vote resultsItem 5.07
  21. May 20, 2025Trademark
    Trademark application: ZAVTAMZI
  22. May 20, 2025Trademark
    Trademark application: ZYVICTOS
  23. May 20, 2025Trademark
    Trademark application: ZAVZY
  24. Mar 31, 20258-K
    Director or officer changeItem 5.02
  25. Mar 27, 2025Trademark
    Trademark application: ZANVICTA
  26. Feb 11, 202510-K
    Annual report (10-K)0 risk factors added, 0 removed
  27. Feb 6, 202410-K
    Annual report (10-K)1 risk factors added, 1 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Moderna MRNA$2.2B−$1.2BJun 30, 2026
United Therapeutics UTHR$3.1B$1.1BJun 30, 2026
Neurocrine Biosciences NBIX$3.4B$0.6BJun 30, 2026
Halozyme HALO$1.7B$0.8BJun 30, 2026
Insmed INSM$1.1B−$0.8BJun 30, 2026
Incyte INCY$5.4B—Mar 31, 2026
Caris Life Sciences CAI$1.0B$0.1BJun 30, 2026
Repligen RGEN$0.8B$0.1BJun 30, 2026

Identity

SEC CIK
939767
LEI
254900PJQB59O2O95R37
Wikidata
Q5419989

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.